CHEMOCENTRYX INC's ticker is CCXI and the CUSIP is 16383L106. A total of 151 filers reported holding CHEMOCENTRYX INC in Q3 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $10,170,000 | +90.9% | 196,900 | -8.4% | 0.14% | +89.2% |
| Q2 2022 | $5,328,000 | -70.1% | 215,000 | -69.7% | 0.07% | -65.4% |
| Q1 2022 | $17,791,000 | +114.5% | 709,689 | +211.5% | 0.21% | +132.6% |
| Q4 2021 | $8,295,000 | -77.4% | 227,800 | -89.4% | 0.09% | -78.0% |
| Q3 2021 | $36,650,000 | +411.6% | 2,143,282 | +300.6% | 0.42% | +345.7% |
| Q2 2021 | $7,164,000 | +71.3% | 535,000 | +555.6% | 0.09% | +3.3% |
| Q1 2021 | $4,183,000 | -60.9% | 81,600 | -58.2% | 0.09% | -63.6% |
| Q3 2020 | $10,686,000 | -74.7% | 195,000 | -73.4% | 0.25% | -82.2% |
| Q2 2020 | $42,238,000 | +424.0% | 734,097 | +266.0% | 1.41% | +208.6% |
| Q1 2020 | $8,060,000 | +48.5% | 200,600 | +46.2% | 0.46% | +149.2% |
| Q4 2019 | $5,428,000 | +791.3% | 137,201 | +52.4% | 0.18% | +471.9% |
| Q3 2019 | $609,000 | +81.8% | 90,000 | +150.0% | 0.03% | +88.2% |
| Q2 2019 | $335,000 | -3.7% | 36,000 | +44.0% | 0.02% | -10.5% |
| Q1 2019 | $348,000 | – | 25,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 276,400 | $4,726,000 | 1.88% |
| TANG CAPITAL MANAGEMENT LLC | 500,000 | $8,550,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 94,300 | $7,131,000 | 1.72% |
| Integral Health Asset Management, LLC | 300,000 | $5,130,000 | 1.48% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 139,200 | $2,380,000 | 1.35% |
| MANGROVE PARTNERS IM, LLC | 686,300 | $11,736,000 | 1.05% |
| Ikarian Capital, LLC | 600,000 | $10,261,000 | 0.72% |
| Ikarian Capital, LLC | 600,000 | $10,260,000 | 0.72% |
| Sofinnova Investments, Inc. | 517,708 | $8,853,000 | 0.52% |
| Birchview Capital, LP | 25,000 | $428,000 | 0.29% |